

FORM PTO-1449B INFORMATION DISCLOSURE CITATION		Attorney Docket: 4439-4044	Serial No.: 10/583,058
		Applicant: NOGUCHI, et al.	
		Filing Date: TBA	Group Art Unit: TBA
NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	1.	Cui T. et al., "Angiotensin II Subtype 2 Receptor Activation Inhibits Insulin-Induced Phosphoinositide 3-Kinase And Akt And Induces Apoptosis In PC12W Cells", <u>Molecular Endocrinology</u> , Vol. 16, No. 9, pgs. 2113-2123, (2001).	
	2.	French S. W. et al., "A Modeled Hydrophobic Domain On The TCL1 Oncoprotein Mediates Association With AKT At The Cytoplasmic Membrane", <u>Biochemistry</u> , No. 41, pgs. 6376-6382 (2002).	
	3.	Hiromura M. et al., "Inhibition Of Akt Kinase Activity By A Peptide Spanning The β A Strand Of The Proto-oncogene TCL1", <u>The Journal of Biological Chemistry</u> , Vol. 279, No. 51, pgs. 53407-53418, (December 2004).	
	4.	Martelli AM et al., "A New Selective AKT Pharmacological Inhibitor Reduces Resistance to Chemotherapeutic Drugs, TRAIL, All-Trans-Retinoic Acid, And Ionizing Radiation Of Human Leukemia Cells", <u>MTT Leukemia</u> , Vol. 17, pgs. 1794-1805 (2003).	
	5.	Ming X. et al., "Rho GTPase/Rho Kinase Negatively Regulates Endothelial Nitric Oxide Synthase Phosphorylation Through The Inhibition of Protein Kinase B/Akt in Human Endothelial Cells", <u>Molecular and Cellular Biology</u> , Vol. 22, No. 24, pgs. 8467-8477, (December 2002).	
	6.	Noguchi M. et al., "Proto-oncogene TCL1: More Than Just A Coactivator For Akt", <u>The Faseb Journal</u> , Vol. 21, pgs. 2273-2284 (August 2007).	
	7.	Supplementary Partial European Search Report for the related European Application No. 04807007.2-1212, Completion of the European Search: 2 August 2007; Date of Mailing 16 October 2007.	
	8.	Supplementary Partial European Search Report for the related European Application No. 04771321.9, Completion of the European Search: 20 November 2007; Date of Mailing 30 November 2007.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.